Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06074562 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 405
- Enrollment target
NCT06074562: Completed Phase 2 study, sponsored by Eli Lilly and Company.
NCT06074562 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 405 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (205% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06074562, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 405 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropathic pain (DPNP). The study will lasts approximately 24 weeks, across 3 study periods.
Primary Outcome
* The NRS was a single-item numeric scale used to describe pain severity. Participants were asked to rate their average pain over the past 24 hours, on a scale of 0 to 10: 0 = no pain, and 10 = pain as bad as you can imagine; a higher score indicates worse outcome (greater pain severity). * The mixed-model repeated measures (MMRM) model included the fixed, centered, categorical effects of region, baseline NRS average pain score, as well as concurrent use of allowed concomitant medications (yes v
Interventions
- DRUG Placebo
- DRUG LY3556050
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 405 participants |
| Start Date | 2023-10-05 |
| Est. Completion | 2025-06-11 |
| Phase | Phase 2 |
What the finished NCT06074562 record still lists
NCT06074562 is an interventional study that assigns participants to a tested intervention. The registered 405 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (205% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06074562 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06074562 about?
NCT06074562 is a clinical study titled "A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain". The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropathic pain (DPNP). The study will lasts approximately 24 weeks, across 3 study periods.
What is the current status of trial NCT06074562?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 405 participants. The study started on 2023-10-05. Estimated completion is 2025-06-11.
What interventions are being tested in trial NCT06074562?
The interventions under investigation include: Placebo (DRUG), LY3556050 (DRUG).
Who is sponsoring clinical trial NCT06074562?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06074562's enrollment target sits among peer trials
405 95th of 2000 higher than 1,906 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05576350 · 405 participants · NA
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
- NCT07066657 · 405 participants · Phase 1
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- NCT06223360 · 406 participants · Phase 2
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
- NCT06411769 · 406 participants · NA
Evidence-based Intervention to Improve Walking Engagement in El Paso, Texas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI